Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470211 | 0.90 | USP30 (0.39) | CTSLCTSSCTSKCTSCUSP30 | |
| SCHEMBL23069425 | 0.90 | USP30 (0.39) | CTSLCTSSCTSKCTSCUSP30 | |
| SCHEMBL23069408 | 0.89 | LRRK2 (0.39) | LRRK2MALT1UGCGEGLN1KDM1A | |
| SCHEMBL26390199 | 0.87 | CTSL (0.42) | CTSLCTSSCTSKCTSCUSP30 | |
| SCHEMBL26388488 | 0.87 | CTSL (0.42) | CTSLCTSSCTSKCTSCUSP30 | |
| SCHEMBL23085845 | 0.86 | LRRK2 (0.37) | CTSSCTSKUSP30LRRK2MALT1 | |
| SCHEMBL29158564 | 0.86 | LRRK2 (0.37) | CTSSCTSKUSP30LRRK2MALT1 | |
| SCHEMBL29158567 | 0.86 | LRRK2 (0.37) | CTSSCTSKUSP30LRRK2MALT1 | |
| SCHEMBL29470224 | 0.86 | LRRK2 (0.37) | CTSSCTSKUSP30LRRK2MALT1 | |
| SCHEMBL23069421 | 0.83 | LRRK2 (0.39) | LRRK2MALT1UGCGEGLN1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4025573-B9 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2024-11-20 | — | — | EP | claimed |
| EP-4025573-B1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2024-07-24 | — | — | EP | claimed |
| CN-114341133-B | Substituted cyanopyrrolidines having USP30 inhibitor activity | 特殊治疗有限公司 | 2024-02-27 | — | — | CN | claimed |
| EP-4025573-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-07-13 | — | — | EP | claimed |
| CN-114341133-A | Substituted cyanopyrrolidines with USP30 inhibitor activity | 特殊治疗有限公司 | 2022-04-12 | — | — | CN | claimed |
| EP-4025573-B9 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2024-11-20 | — | — | EP | disclosed |
| EP-4025573-B1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2024-07-24 | — | — | EP | disclosed |
| CN-114341133-B | Substituted cyanopyrrolidines having USP30 inhibitor activity | 特殊治疗有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20220315572-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-4025573-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-07-13 | — | — | EP | disclosed |
| CN-114341133-A | Substituted cyanopyrrolidines with USP30 inhibitor activity | 特殊治疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021043870-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021043870-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315572-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP36, USP28 | CTSL 877/4885CTSS 1696/4885CTSK 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.